Bagging Qiagen, CytoPathfinder Picks Up siRNAs, Partner With Global Reach for Its Microarray Tools | GenomeWeb

CytoPathfinder, a Japanese startup developing microarrays and drug-delivery technologies, last week said that Qiagen will supply it siRNAs for use on its transfection microarray for high-throughput RNAi screening.

CytoPathfinder said the deal not only gives it access to Qiagen's HiPerformance siRNA design algorithm, which it licensed from Novartis in late 2003 (see RNAi News, 12/19/2003), but a partner with a global reach — something that could prove vital for the Japanese startup as it eyes overseas markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.